POTASSIUM CHLORIDE IN SODIUM CHLORIDE
RxNorm 637551· SODIUM CHLORIDE AND POTASSIUM CHLORIDE· INTRAVENOUS
B. Braun Medical Inc.
Indications and usage
INDICATIONS AND USAGE Potassium Chloride in 0.9% Sodium Chloride Injection is indicated for use in adults and pediatric patients as a source of electrolytes and water for hydration.
Dosage and administration
DOSAGE AND ADMINISTRATION This solution is for intravenous use. Dosage is to be directed by a physician and is dependent upon age, weight, clinical condition of the patient and laboratory determinations. Frequent laboratory determinations and clinical evaluation are essential to monitor changes in blood glucose and electrolyte concentrations, and fluid and electrolyte balance during prolonged parenteral therapy. When a hypertonic solution is to be administered peripherally, it should be slowly infused through a small bore needle, placed well within the lumen of a large vein to minimize venous irritation. Carefully avoid infiltration. In the average adult, daily requirements of sodium and chloride are met by the infusion of one liter of 0.9% sodium chloride (154 mEq each of sodium and chloride). Usually up to 40 mEq of potassium per liter daily is sufficient to replace normal loss in adults. Infusion rates should not exceed 10 mEq per hour or 120 mEq per day. A liter of fluid containing 40 mEq of potassium should be administered over an 8-hour period. Fluid administration should be based on calculated maintenance or replacement fluid requirements for each patient. Pediatric Dosage and Administration. There is no specific pediatric dose. The dose is dependent on weight, clinical condition and laboratory results. See WARNINGS and PRECAUTIONS . Some additives may be incompatible. Consult with pharmacist. When introducing additives, use aseptic techniques. Mix thoroughly. Do not store. Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit.
Warnings
WARNINGS The administration of intravenous solutions can cause fluid and/or solute overload resulting in dilution of serum electrolyte concentrations, overhydration, congested states or pulmonary edema. The risk of dilutional states is inversely proportional to the electrolyte concentration. The risk of solute overload causing congested states with peripheral and pulmonary edema is directly proportional to the electrolyte concentration. Solutions containing sodium ions should be used with great care, if at all, in patients with congestive heart failure, severe renal insufficiency, and in clinical states in which there is sodium retention with edema. Infusion of isotonic (0.9%) sodium chloride during or immediately after surgery may result in excessive sodium retention. Use the patient's circulatory system status as a guide. In patients with diminished renal function, administration of solutions containing sodium or potassium ions may result in sodium or potassium retention. Solutions containing potassium ions should be used with great care, if at all, in patients with hyperkalemia, severe renal failure, and in conditions in which potassium retention is present.
Contraindications
CONTRAINDICATIONS Potassium Chloride in 0.9% Sodium Chloride Injection is contraindicated in clinical conditions where additives of sodium, potassium or chloride could be clinically detrimental.
Pregnancy
Pregnancy: Teratogenic Effects Animal reproduction studies have not been conducted with Potassium Chloride in 0.9% Sodium Chloride Injection. It is also not known whether Potassium Chloride in 0.9% Sodium Chloride Injection can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. Potassium Chloride in 0.9% Sodium Chloride Injection should be given to a pregnant woman only if clearly needed.
Nursing mothers
Nursing Mothers It is not known whether this drug is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when Potassium Chloride in 0.9% Sodium Chloride Injection is administered to a nursing woman.
Adverse events
Most frequently reported events (FDA FAERS). Report frequency does not imply causation.
- death18
- product label confusion6
- infusion related reaction4
- infusion site pain4
- product packaging confusion4
- vein disorder4
- discomfort3
- hypokalaemia3
- product label issue3
- product name confusion3
- sepsis3
- acute kidney injury2
- blood potassium increased2
- diarrhoea2
- dyspnoea2
- flushing2
Adverse reactions (label)
ADVERSE REACTIONS Reactions which may occur because of the solution or the technique of administration include febrile response, infection at the site of injection, venous thrombosis or phlebitis extending from the site of injection, extravasation, and hypervolemia. Too rapid infusion of hypertonic solutions may cause local pain and venous irritation. Rate of administration should be adjusted according to tolerance. Use of the largest peripheral vein and a small bore needle is recommended. (See DOSAGE AND ADMINISTRATION .) Symptoms may result from an excess or deficit of one or more of the ions present in the solution; therefore, frequent monitoring of electrolyte levels is essential. Hypernatremia may be associated with edema and exacerbation of congestive heart failure due to the retention of water, resulting in an expanded extracellular fluid volume. Reactions reported with the use of potassium-containing solutions include nausea, vomiting, abdominal pain and diarrhea. The signs and symptoms of potassium intoxication include paresthesias of the extremities, areflexia, muscular or respiratory paralysis, mental confusion, weakness, hypotension, cardiac arrhythmias, heart block, electrocardiographic abnormalities and cardiac arrest. Potassium deficits result in disruption of neuromuscular function, and intestinal ileus and dilatation. If infused in large amounts, chloride ions may cause a loss of bicarbonate ions, resulting in an acidifying effect. The physician should also be alert to the possibility of adverse reactions to drug additives. Prescribing information for drug additives to be administered in this manner should be consulted. If an adverse reaction does occur, discontinue the infusion, evaluate the patient, institute appropriate therapeutic countermeasures and save the remainder of the fluid for examination if deemed necessary.
KR · 한국Products in Korea (55)
- 뮤로128점안액2%(염화나트륨)(주)바슈헬스코리아
- 뮤로128점안액5%(염화나트륨)(주)바슈헬스코리아
- 페스비강분무액(염화나트륨)(주)엔터팜
- 페스비강분무액(염화나트륨)(주)엔터팜
- 페스리틀비강액(염화나트륨)(소아용)(주)엔터팜
- 페스리틀비강액(염화나트륨)(소아용)(주)엔터팜
- 페스시누클린즈분무액(염화나트륨)(주)엔터팜
- 페스시누클린즈분무액(염화나트륨)(주)엔터팜
- 페스시누클린즈분무액(염화나트륨)(주)엔터팜
- 대한관류용멸균생리식염수대한약품공업(주)
- 대한3%염화나트륨액대한약품공업(주)
- 피스코점비액(염화나트륨)동아에스티(주)
- 피스코점비액(염화나트륨)동아에스티(주)
- 피스코점비액(염화나트륨)동아에스티(주)
- 피스코점비액(염화나트륨)동아에스티(주)
- 피스코점비액(염화나트륨)동아에스티(주)
- 피스코점비액(염화나트륨)동아에스티(주)
- 피스코점비액(염화나트륨)동아에스티(주)
- 씨알알티에스에이취비아이씨삼십오용액비브라운코리아(주)
- 씨알알티에스에이취비아이씨삼십오용액비브라운코리아(주)
View more: Full FDA label on DailyMed →Label effective 20250711